$LGI

LAZARD GLOBAL TOTAL RETURN AND INCOME FUND DECLARES MONTHLY DISTRIBUTION AND ISSUES ESTIMATED SOURCES OF THE DISTRIBUTION ANNOUNCED IN SEPTEMBER

Lazard Global Total Return and Income Fund (LGI) declared a monthly distribution of $0.15340 per share, payable on November 24, 2026. The Fund estimates that it has distributed more than its net investment income and net realized capital gains, with a portion being return of capital. The Fund's investment objective is total return, consisting of capital appreciation and current income, and is managed by Lazard Asset Management (LAM), an indirect subsidiary of Lazard, Inc. (LAZ).

Original reporting
Published Oct 22, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
LAZARD GLOBAL TOTAL RETURN AND INCOME FUND DECLARES MONTHLY DISTRIBUTION AND ISSUES ESTIMATED SOURCES OF THE DISTRIBUTION ANNOUNCED IN SEPTEMBER — source image
Decision brief

The 30-second read

$LGINeutralLow
01

Why it matters

The announcement provides the first public disclosure of the distribution amount and its composition, which could influence investor perception of the fund's cash flow and tax treatment.

02

Market read

The news is primarily relevant to current shareholders and income‑seeking investors; broader market impact is limited.

03

What to watch

The distribution size is modest and may simply reflect routine cash management rather than underlying performance concerns.

Relevance 4/10Novelty 3/10Timing: today

Background

Lazard Global Total Return and Income Fund (LGI) issued a press release confirming its monthly distribution and detailing the sources of the payout.

Company-level read

Ticker impact

$LGINeutralHigh confidence
Context

LGI announced a monthly cash distribution of $0.15340 per share, including a portion classified as return of capital.

Expected impact

likely modest downside as the market prices in the return of capital element

Evidence & confidence

Return of capital distributions are often viewed as a negative signal for future earnings, prompting modest share sell‑off.

Market effects

Minimal impact on the broader equity or fixed‑income markets; primarily relevant to income‑focused investors.

No significant regional effect; the fund is US‑based with global holdings.

Limited relevance beyond the fund's shareholder base.

Counterpoint

Some investors may view the return of capital as a sign of limited growth prospects and could short the fund.

Key entities

  • Lazard Global Total Return and Income Fund, Inc.

    Issuer of the distribution.

  • Lazard, Inc.

    Parent of the fund's investment manager.

Related articles

$ALOYMed

Why Trump Can't Afford to Lose The Rare Earth Race

REalloys (NASDAQ: ALOY) has assembled a rare earth manufacturing process from feedstock to magnet production, aiming to reduce reliance on China. The company secured raw materials, built a metallization platform, and partnered for magnet manufacturing. It raised $100M to finance its operations, targeting commercial production by early 2027 to meet Pentagon demand for non-Chinese rare earth magnets.

$NBISHigh

Nebius borrows $3.5 billion as investors question neocloud debt

Nebius Group N.V. (NBIS) secured a $3.5 billion loan from Citigroup, maturing in 364 days. The company's revenue chief noted rising AI computing prices and distinguished Nebius from CoreWeave Inc. (CRWV) regarding debt levels. The loan, priced at Term SOFR plus 2.75-3.5%, will fund data centers and GPUs, adding to existing convertible bonds. Nebius also began publishing live spot prices for GPU capacity, aiming to optimize long-term financing costs.

$ZLABHighAI 9/10

Zai Lab Limited Prices $250M PIPE at $22.04 Per ADS

Zai Lab Limited announced a private placement of 11.34 million American Depositary Shares (ADSs) at $22.04 each, raising $250 million. The deal is expected to close by October 27, 2026, subject to conditions. The funds will support the development of an oncology asset.